Theriva Biologics Out-Licenses SYN-020 to Rasayana for $38M Potential Deal
Event summary
- Theriva Biologics licensed SYN-020 to Rasayana Therapeutics for multiple indications, receiving a $300,000 upfront payment and potential $38M in milestones.
- SYN-020 is an oral recombinant bovine intestinal alkaline phosphatase (IAP) designed to reduce fat absorption, intestinal inflammation, and promote a healthy microbiome.
- Rasayana assumes all development and commercialization costs for SYN-020, which is poised to enter Phase 2 clinical testing.
- Theriva will focus on its lead pancreatic cancer program, VCN-01, following the out-licensing.
The big picture
This deal reflects a strategic pivot for Theriva, allowing it to monetize a non-core asset while focusing on its oncology pipeline. The $38M potential deal underscores the growing interest in gut-targeted therapies for chronic inflammatory diseases, aligning with broader industry trends toward healthspan extension and microbiome-focused treatments. Rasayana's expertise in Gut-Organ axis biology positions it to advance SYN-020, potentially unlocking high-value indications in metabolic and inflammatory disorders.
What we're watching
- Clinical Progress
- Whether SYN-020 can successfully navigate Phase 2 trials under Rasayana's leadership and deliver meaningful patient outcomes.
- Revenue Potential
- The pace at which Rasayana can achieve development and commercialization milestones to trigger Theriva's milestone payments and royalties.
- Strategic Focus
- How Theriva's decision to out-license SYN-020 will impact its ability to advance its lead pancreatic cancer program, VCN-01.
Related topics